Aug 5, 2026 – 12.39pmMayne Pharma investors are calling for the sale of its women’s health and dermatology businesses in the US, after the federal government’s decision to block a takeover of the Adelaide-based company last year left them nursing heavy losses.Key shareholders, including offshore hedge funds and activist investors who now make up more than 20 per cent of Mayne’s share register, are putting pressure on chairman Bruce Robinson to start a strategic review of the group’s assets.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Fetching latest articles
Mayne Pharma investors push for break-up after blocked takeover bid
Investors in the Adelaide-based company are not ruling out seeking a board spill if management fails to take drastic action to increase shareholder value.
TL;DRAI
Mayne Pharma investors (>20% stake) push break-up of US women's health and dermatology after regulatory block of takeover. Regulatory M&A failure forces portfolio restructuring: capital redeployment pivots from growth to asset sales, redefines corporate capital-efficiency strategy.
100 words~1 min read
